ISSCR News
Global Collaboration: The Spirit of the ISSCR
It is a great honor for me to assume the ISSCR Presidency during the 20th anniversary year of the Society’s founding. In the past 20 years, the ISSCR has embodied our shared passion for stem cell research. Thanks to all of you, the ISSCR became the world’s preeminent Society for stem cell research. The remarkable growth of the ISSCR is driven by our members’ exciting research and discoveries, many of which are being translated into life-saving treatments and new approaches in drug development for the benefit of humanity.
Celebrating 20 Years of Innovation: 2021-2022: A Year in Review
As the ISSCR turns 20 this year, it is humbling to reflect on the exceptional stem cell achievements during that time and the many contribution of our Society. We can celebrate the curiosity, ingenuity, and persistence of our members that has yielded significant advances in stem cell research and regenerative medicine since those early days.
Possibilities Start Here
We have tremendous opportunities in the society for early career scientists both at the 2022 Annual Meeting and throughout they year, and do I thought it was the perfect time to share all of the ways to engage.
The Future Is Now
We’ve seen some extraordinary stem cell advances reaching the clinic. A recent clinical trial could have a significant impact on patients with Type 1 diabetes. Advances in cell therapy for the treatment of Parkinson’s disease, and a stem cell-derived model that has enabled researchers to identify drug candidates that may slow dry age-related macular degeneration (AMD). These are only a few of the potential ways stem cell science is positioned to make significant impact on the treatment of devastating diseases.
Advocating for Regulations that Facilitate Safe and Efficacious Therapies
Last December, nearly 40 professionals with the U.S. Food and Drug Administration (FDA) gathered with ISSCR leaders to discuss advances in the development of stem cell therapies. The attendance of FDA leaders – Peter Marks, Director, Center for Biologics Evaluation and Research (CBER), Celia Witten, Deputy Director, CBER, and Wilson Bryan, Director, Office of Tissues and Advanced Therapies (OTAT) – signals how important it is for the agency to discuss scientifically informed recommendations from the ISSCR as new stem cell-based therapies advance.
Receive ISSCR Press Releases
Sign up be a part of ISSCR’s media list. Media Contact: Kym Kilbourne, Director of Media and Strategic Communications
Subscribe to ISSCR News.
Each month, ISSCR delivers scientific, policy, and community to your inbox .